Recombinant CRM197 made in Pfenex Expression Technology®
Research and GMP grade, from milligrams to kilograms.
Proven platformCRM197 produced in the Pfenex platform is in CAPVAXIVE®, VAXNEUVANCE®, Pneumosil® and MenFive®
Since 2011GMP certification since 2011
DMF on fileDrug Master File maintained with the US FDA
Highest purityHighest purity CRM197 commercially available.1
Research grade
Add to cart, or request a quote for larger quantities.
New customer? Get a free CRM197 sample with code newcustomer at checkout. Shipping not included.
Lyophilized 1 mg
$250.00Add to cart
Lyophilized 20 mg
$2,000.00Add to cart
Frozen 20 mg
$2,000.00Add to cart
| Description | PeliCRM197® diphtheria toxin mutant, recombinant. A non-toxic mutant with a single amino acid substitution of glycine to glutamic acid at position 52.2 Research grade. |
|---|---|
| Source | Pseudomonas fluorescens |
| Purity | > 95% CRM197 by RP-HPLC |
| Endotoxin | < 50 EU/mg of protein |
| Dimers and HMW impurities | < 5% by SE-HPLC |
| Lyophilized | Store at 2 to 8 °C. Reconstitute with sterile deionized water before use. |
| Frozen | Store below -60 °C. Thaw before use. |
Need GMP-grade CRM197?GMP-Grade PeliCRM197® is available now.
References
- 1.Analytical Comparability Assessments of 5 Recombinant CRM197 Proteins from Different Manufacturers and Expression Systems. Hickey, J.M., et al. Journal of Pharmaceutical Sciences, July 2018.
- 2.The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Giannini, G., et al. Nucleic Acids Research, May 25, 1984.
CAPVAXIVE® and VAXNEUVANCE® are registered trademarks of Merck. Pneumosil® and MenFive® are registered trademarks of Serum Institute of India Pvt. Ltd.
